de Aguiar Ferreira, C.; Heidari, P.; Ataeinia, B.; Sinevici, N.; Granito, A.; Kumar, H.M.; Wehrenberg-Klee, E.; Mahmood, U.
Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide. Pharmaceutics 2022, 14, 1460.
https://doi.org/10.3390/pharmaceutics14071460
AMA Style
de Aguiar Ferreira C, Heidari P, Ataeinia B, Sinevici N, Granito A, Kumar HM, Wehrenberg-Klee E, Mahmood U.
Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide. Pharmaceutics. 2022; 14(7):1460.
https://doi.org/10.3390/pharmaceutics14071460
Chicago/Turabian Style
de Aguiar Ferreira, Carolina, Pedram Heidari, Bahar Ataeinia, Nicoleta Sinevici, Alyssa Granito, Hritik Mahajan Kumar, Eric Wehrenberg-Klee, and Umar Mahmood.
2022. "Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide" Pharmaceutics 14, no. 7: 1460.
https://doi.org/10.3390/pharmaceutics14071460
APA Style
de Aguiar Ferreira, C., Heidari, P., Ataeinia, B., Sinevici, N., Granito, A., Kumar, H. M., Wehrenberg-Klee, E., & Mahmood, U.
(2022). Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide. Pharmaceutics, 14(7), 1460.
https://doi.org/10.3390/pharmaceutics14071460